Poser, Wolfgang

[["dc.bibliographiccitation.firstpage","469"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Drug and Alcohol Review"],["dc.bibliographiccitation.lastpage","470"],["dc.bibliographiccitation.volume","19"],["dc.contributor.author","Vormfelde, Stefan Viktor"],["dc.contributor.author","Poser, Wolfgang"],["dc.date.accessioned","2018-11-07T10:31:00Z"],["dc.date.available","2018-11-07T10:31:00Z"],["dc.date.issued","2000"],["dc.identifier.isi","000165996100014"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/43993"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Carfax Publishing"],["dc.relation.issn","0959-5236"],["dc.title","How to count methadone-related deaths"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.subtype","letter_note"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","86"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Alcoholism: Clinical and Experimental Research"],["dc.bibliographiccitation.lastpage","95"],["dc.contributor.author","Krampe, Henning"],["dc.contributor.author","Stawicki, Sabina"],["dc.contributor.author","Wagner, Thilo"],["dc.contributor.author","Bartels, Claudia"],["dc.contributor.author","Aust, Carlotta"],["dc.contributor.author","Rüther, Eckart"],["dc.contributor.author","Poser, Wolfgang"],["dc.contributor.author","Ehrenreich, Hannelore"],["dc.date.accessioned","2017-09-07T11:46:33Z"],["dc.date.available","2017-09-07T11:46:33Z"],["dc.date.issued","2006"],["dc.description.abstract","Objective: (1) To perform a 9-year study of abstinence, lapse, and relapse in 180 chronic alcoholic patients, participants of the Outpatient Longterm Intensive Therapy for Alcoholics (OLITA); (2) To investigate the role of supervised alcohol deterrents (AD) in relapse prevention and as an adjunct for maintenance of long-term abstinence. Method: This prospective open treatment study evaluates the long-term course of drinking outcomes and AD use of 180 chronic alcoholics consecutively admitted from 1993 to 2002. Subsamples are compared for (1) sham-AD versus verum-AD (disulfiram/calcium carbimide), (2) coped lapses versus finally detrimental lapses versus malignant relapses, and (3) AD use for 13 to 20 versus {.extbackslash}textgreater 20 months. Results: In this 9-year study, the cumulative probability of not having relapsed was 0.52, and that of not having consumed any alcohol was 0.26. Despite long-term use, disulfiram/calcium carbimide was well tolerated. Patients on sham-AD (due to contraindications to verum-AD) showed higher cumulative abstinence probability than patients on verum (S {.extbackslash}textequals 0.86 vs. S {.extbackslash}textequals 0.49, p {.extbackslash}textequals 0.03). Detrimental lapses and malignant relapses occurred earlier than successfully coped lapses (p {.extbackslash}textless 0.001); patients with detrimental lapse and with malignant relapse had rewer days of AD intake and less subsequent days without AD than patients with coped lapse (p {.extbackslash}textless 0.001). The cumulative abstinence probability was S {.extbackslash}textequals 0.75 for patients with long-term intake compared with S {.extbackslash}textequals 0.50 for patients who stopped AD between months 13 and 20 (p {.extbackslash}textless 0.001). Conclusions: An abstinence rate of {.extbackslash}textgreater 50{.extbackslash}textpercent in this 9-year study strongly supports the concept of comprehensive, long-term outpatient treatment of alcoholics. Supervised, guided intake of AD, also over extended periods, can be used as a predominantly psychologically acting ingredient of successful alcoholism therapy."],["dc.identifier.doi","10.1111/j.1530-0277.2006.00013.x"],["dc.identifier.gro","3150523"],["dc.identifier.pmid","16433735"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/7295"],["dc.language.iso","en"],["dc.notes.status","zu prüfen"],["dc.relation.issn","0145-6008"],["dc.title","Follow-up of 180 alcoholic patients for up to 7 years after outpatient treatment: Impact of alcohol deterrents on outcome"],["dc.type","journal_article"],["dc.type.internalPublication","unknown"],["dc.type.peerReviewed","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","7"],["dc.bibliographiccitation.journal","European Journal of Clinical Pharmacology"],["dc.bibliographiccitation.volume","58"],["dc.contributor.author","Poser, Wolfgang"],["dc.date.accessioned","2018-11-07T09:58:38Z"],["dc.date.available","2018-11-07T09:58:38Z"],["dc.date.issued","2002"],["dc.format.extent","S90"],["dc.identifier.isi","000179032800080"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/37404"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.publisher.place","New york"],["dc.relation.conference","4th Annual Congress on Clinical Pharmacology"],["dc.relation.eventlocation","WIESBADEN, GERMANY"],["dc.relation.issn","0031-6970"],["dc.title","Predicting the potential for abuse and dependence of new drugs"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","271"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Acta Neuropathologica"],["dc.bibliographiccitation.lastpage","276"],["dc.bibliographiccitation.volume","101"],["dc.contributor.author","Siren, A. L."],["dc.contributor.author","Knerlich, F."],["dc.contributor.author","Poser, Wolfgang"],["dc.contributor.author","Gleiter, Christoph H."],["dc.contributor.author","Bruck, Wolfgang W."],["dc.contributor.author","Ehrenreich, Hannelore"],["dc.date.accessioned","2018-11-07T09:17:30Z"],["dc.date.available","2018-11-07T09:17:30Z"],["dc.date.issued","2001"],["dc.description.abstract","Using immunohistochemistry, expression of erythropoietin (EPO), a hypoxia-inducible neuroprotective factor, and its receptor (EPOR) were investigated in human brain tissue after ischemia/hypoxia. Autopsy brains of neuropathologically normal subjects were compared to those with ischemic infarcts or hypoxic damage. In normal brain, weak EPO/EPOR immunoreactivity was mainly neuronal. In fresh infarcts, EPO immunoreactivity appeared in vascular endothelium, EPOR in microvessels and neuronal fibers. In older infarcts reactive astrocytes exhibited EPO/EPOR immunoreactivity. Acute hypoxic brain damage was associated with vascular EPO expression, older hypoxic damage with EPO/EPOR immunoreactivity in reactive astrocytes. The pronounced up-regulation of EPO/EPOR in human ischemic/hypoxic brains underlines their role as an endogenous neuroprotective system and suggests a novel therapeutic potential in cerebrovascular disease for EPO, a clinically well-characterized and safe compound."],["dc.identifier.isi","000167526200013"],["dc.identifier.pmid","11307627"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/28185"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","0001-6322"],["dc.title","Erythropoietin and erythropoietin receptor in human ischemic/hypoxic brain"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","The International Journal of Neuropsychopharmacology"],["dc.bibliographiccitation.volume","13"],["dc.contributor.author","Degner, Detlef"],["dc.contributor.author","Poser, Wolfgang"],["dc.contributor.author","Bleich, Stefan"],["dc.contributor.author","Ruether, Eckhart"],["dc.date.accessioned","2018-11-07T08:47:50Z"],["dc.date.available","2018-11-07T08:47:50Z"],["dc.date.issued","2010"],["dc.format.extent","49"],["dc.identifier.isi","000281281100169"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/21059"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Cambridge Univ Press"],["dc.publisher.place","New york"],["dc.relation.conference","27th CINP Congress Meeting 2010"],["dc.relation.eventlocation","Hong Kong, PEOPLES R CHINA"],["dc.relation.issn","1461-1457"],["dc.title","Pontine myelinolysis and hyponatremia associated with carbamazepine treatment in patients with alcohol dependence"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Der Nervenarzt"],["dc.bibliographiccitation.volume","78"],["dc.contributor.author","Havemann-Reinecke, Ursula"],["dc.contributor.author","Wacker, S."],["dc.contributor.author","Weissbeck-Schauenburg, R."],["dc.contributor.author","Schauenburg, Henning"],["dc.contributor.author","Poser, Wolfgang"],["dc.date.accessioned","2018-11-07T10:57:21Z"],["dc.date.available","2018-11-07T10:57:21Z"],["dc.date.issued","2007"],["dc.format.extent","162"],["dc.identifier.isi","000253318800331"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/50222"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.publisher.place","New york"],["dc.relation.issn","0028-2804"],["dc.title","Short term combined outpatient-inpatient group psychotherapy for alcohol and benzodiazepine dependence - concept and results"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Pharmacopsychiatry"],["dc.bibliographiccitation.volume","38"],["dc.contributor.author","Krampe, Henning"],["dc.contributor.author","Stawicki, Sabina"],["dc.contributor.author","Wagner, T."],["dc.contributor.author","Bartels, C."],["dc.contributor.author","Ruther, Eckart"],["dc.contributor.author","Poser, Wolfgang"],["dc.contributor.author","Ehrenreich, Hannelore"],["dc.date.accessioned","2018-11-07T10:56:35Z"],["dc.date.available","2018-11-07T10:56:35Z"],["dc.date.issued","2005"],["dc.format.extent","257"],["dc.identifier.isi","000232591900140"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/50048"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Georg Thieme Verlag Kg"],["dc.publisher.place","Stuttgart"],["dc.relation.conference","24th Symposium of the Arbeitsgemeinschaft-fur-Neuropsychopharmakologie-und-Pharmakopsychiatrie (AGNP)"],["dc.relation.eventlocation","Munich, GERMANY"],["dc.relation.issn","0176-3679"],["dc.title","Longterm follow-up of 180 chronic alcoholics during and after comprehensive integrated outpatient treatment: Relation of deterrent medication (DM) and outcome"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","277"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Therapeutic Drug Monitoring"],["dc.bibliographiccitation.lastpage","283"],["dc.bibliographiccitation.volume","26"],["dc.contributor.author","Meineke, Ingolf"],["dc.contributor.author","Kress, I."],["dc.contributor.author","Poser, Wolfgang"],["dc.contributor.author","Ruther, Eckart"],["dc.contributor.author","Brockmoeller, Juergen"],["dc.date.accessioned","2018-11-07T10:48:48Z"],["dc.date.available","2018-11-07T10:48:48Z"],["dc.date.issued","2004"],["dc.description.abstract","A selective and sensitive HPLC method is described for therapeutic drug monitoring of the antidepressant drug mirtazapine and its active metabolite desmethylmirtazapine. Liquid/solid extraction with C, cartridges was used for cleanup of plasma samples. The chromatographic separation was carried out on a phenylhexyl column. No interference from other coadministered antidepressants has been observed in 234 samples from 184 patients. The calibration range used was from 1 ng/mL to 100 ng/mL. The analytic method has proven robust and well suited for therapeutic drug monitoring. In addition to qualitative and quantitative validation data for the assay method, concentration measurements in samples from patients on mirtazapine therapy and the relevant dosing information are presented. Median drug levels after a 15-mg dose were 37 ng/mL mirtazapine and 20 ng/mL desmethylmirtazapine. When a 60-mg dose was administered, median concentrations of 83 ng/mL mirtazapine and 65 ng/mL desmethylmirtazapine were found."],["dc.identifier.doi","10.1097/00007691-200406000-00010"],["dc.identifier.isi","000222196600009"],["dc.identifier.pmid","15167628"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/48284"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Lippincott Williams & Wilkins"],["dc.relation.issn","0163-4356"],["dc.title","Therapeutic drug monitoring of mirtazapine and its metabolite desmethylmirtazapine by HPLC with fluorescence detection"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","849"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Alcoholism Clinical and Experimental Research"],["dc.bibliographiccitation.lastpage","861"],["dc.bibliographiccitation.volume","27"],["dc.contributor.author","Doring, WKH"],["dc.contributor.author","Herzenstiel, M. N."],["dc.contributor.author","Krampe, Henning"],["dc.contributor.author","Jahn, Holger"],["dc.contributor.author","Pralle, L."],["dc.contributor.author","Sieg, S."],["dc.contributor.author","Wegerle, E."],["dc.contributor.author","Poser, Wolfgang"],["dc.contributor.author","Ehrenreich, Hannelore"],["dc.date.accessioned","2018-11-07T10:39:00Z"],["dc.date.available","2018-11-07T10:39:00Z"],["dc.date.issued","2003"],["dc.description.abstract","Background: During alcohol withdrawal and early abstinence, severe alterations of electrolyte and water homeostasis and their regulating hormones are well recognized. Almost nothing is known about regeneration of these functions with long-term abstinence. This cohort study was designed to monitor determinants of electrolyte and water balance over 280 days of abstinence in alcohol-dependent men compared with healthy controls. Methods: Vasopressin (AVP), N-terminal proatrial natriuretic peptide, aldosterone, angiotensin II, and electrolytes, together with major parameters of kidney and liver function, were monitored in 35 male alcoholics aged 44+/-8 years. Of these, 21 could be followed up to 280 days of strictly controlled abstinence due to their participation in the Outpatient Long-Term Intensive Therapy for Alcoholics. The control group comprised 20 healthy male volunteers aged 39+/-7 years. Results: Basal AVP levels were found to be suppressed over the whole study period. In contrast, N-terminal proatrial natriuretic peptide remained increased over all 280 days. No persistent alterations were found for aldosterone or angiotensin II. Sodium and potassium in plasma and urine returned to normal within a few weeks. Creatinine clearance, urea nitrogen in plasma and urine, urinary osmolality, hematocrit, and hemoglobin remained low as compared with controls over the entire study. Conclusions: Chronic alcohol abuse causes severe and persistent alterations in the hormonal regulatory systems of electrolyte and water balance. The suppressed basal secretion of AVP may reflect a dysregulation in the brain that influences the hypothalamic-pituitary-adrenal axis function, mood, memory, addiction behavior, and craving during alcohol abstinence. These findings may provide a ground for future therapeutic approaches to stable abstinence."],["dc.identifier.doi","10.1097/01.ALC.0000065433.17403.DE"],["dc.identifier.isi","000183083500015"],["dc.identifier.pmid","12766631"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/45942"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Lippincott Williams & Wilkins"],["dc.relation.issn","0145-6008"],["dc.title","Persistent alterations of vasopressin and N-terminal proatrial natriuretic peptide plasma levels in long-term abstinent alcoholics"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","619"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","Journal of Psychiatric Research"],["dc.bibliographiccitation.lastpage","635"],["dc.bibliographiccitation.volume","38"],["dc.contributor.author","Wagner, Thilo"],["dc.contributor.author","Krampe, Henning"],["dc.contributor.author","Stawicki, Sabina"],["dc.contributor.author","Reinhold, Jennifer"],["dc.contributor.author","Jahn, Henriette"],["dc.contributor.author","Mahlke, Kristin"],["dc.contributor.author","Barth, Ulrike"],["dc.contributor.author","Sieg, Sonja"],["dc.contributor.author","Maul, Oliver"],["dc.contributor.author","Galwas, Claudia"],["dc.contributor.author","Aust, Carlotta"],["dc.contributor.author","Kröner-Herwig, Birgit"],["dc.contributor.author","Brunner, Edgar"],["dc.contributor.author","Poser, Wolfgang"],["dc.contributor.author","Henn, Fritz"],["dc.contributor.author","Rüther, Eckart"],["dc.contributor.author","Ehrenreich, Hannelore"],["dc.date.accessioned","2017-09-07T11:46:24Z"],["dc.date.available","2017-09-07T11:46:24Z"],["dc.date.issued","2004"],["dc.description.abstract","It is far from clear how comorbidity changes during alcoholism treatment. This study investigates: (1) the course of comorbid Axis I disorders in chronic alcoholics over 2 years of controlled abstinence in the outpatient long-term intensive therapy for alcoholics (OLITA) and (2) the effect of comorbid Axis I and II disorders in this group of patients on subsequent drinking outcome over a four-year follow-up. This prospective treatment study evaluates psychiatric variables of 89 severely affected chronic alcohol dependent patients on admission (t1), month 6 (t2), 12 (t3) and 24 (t4). Drinking outcomes have been analyzed from 1998 to 2002. On admission, 61.8% of the patients met criteria for a comorbid Axis I disorder, 63.2% for a comorbid personality disorder. Axis I disorders remit from t1 (59.0% ill), t2 (38.5%), t3 (28.2%) to t4 (12.8%) (p<0.0001). Anxiety disorders remit more slowly from t1 (43.6%) to t3 (20.5%, p=0.0086), whereas mood disorders remit early between t1 (23.1%) and t2 (5.1%, p=0.0387) with a slight transient increase at t3 (10.3%). During the four-year follow-up, the cumulative probability of not having relapsed amounts to 0.59. Two predictors have a strong negative impact on abstinence probability: number of inpatient detoxifications (p=0.0013) and personality disorders (p=0.0106). The present study demonstrates a striking remission of comorbid Axis I disorders upon abstinence during comprehensive long-term outpatient alcoholism treatment. The presence of an Axis II rather than an Axis I disorder on admission strongly predicts drinking outcome over a four-year follow-up"],["dc.identifier.doi","10.1016/j.jpsychires.2004.04.007"],["dc.identifier.gro","3150506"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/7278"],["dc.language.iso","en"],["dc.notes.status","final"],["dc.relation.issn","0022-3956"],["dc.subject","Outpatient alcoholism treatment; Chronic alcohol dependence; Prognosis; Comorbid personality disorders; Chronicity; Chronic psychiatric illness"],["dc.title","Substantial decrease of psychiatric comorbidity in chronic alcoholics upon integrated outpatient treatment - results of a prospective study"],["dc.type","journal_article"],["dc.type.internalPublication","unknown"],["dc.type.peerReviewed","unknown"],["dspace.entity.type","Publication"]]